Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in the Treatment of Patients With Moderate COVID-19

NCT05770466 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT05770466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05770466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in the Treatment of Patients With Moderate COVID-19
Lead sponsor
National Taiwan University Hospital
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2022
Completion date
January 11, 2023
Enrollment
134 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19